AbbVie (ABBV +0.76%) has not performed well this year, but the company’s recent first-quarter update, released on April 29, helped breathe new life into the stock, which jumped by more than 3% post-earnings. Could this be the start of a sustained rally? It’s hard to say. However, AbbVie’s financial results once again highlighted one of the company’s strengths that investors should pay attention to. Let’s look into it and consider what it means for AbbVie’s prospects.
Image source: The Motley Fool.
AbbVie’s growth pillars are unstoppable
AbbVie’s revenue for the first quarter came in at $15 billion, 12.4% higher than the year-ago period. The company had projected sales of $14.7 billion for the period, so this is a nice surprise. The pharmaceutical leader singled out several areas that drove the revenue beat, including its immunology business. That’s the trend investors shouldn’t…
